Iovance Biotherapeutics I...

AI Score

0

Unlock

5.89
0.11 (1.90%)
At close: Jan 14, 2025, 3:59 PM
5.88
-0.17%
Pre-market Jan 15, 2025, 05:45 AM EST
undefined%
Bid 5.86
Market Cap 1.80B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.34
PE Ratio (ttm) -4.4
Forward PE n/a
Analyst Buy
Ask 6.29
Volume 14,026,951
Avg. Volume (20D) 7,319,298
Open 5.96
Previous Close 5.78
Day's Range 5.87 - 6.44
52-Week Range 5.77 - 18.33
Beta undefined

About IOVA

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or pers...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 15, 2010
Employees 557
Stock Exchange NASDAQ
Ticker Symbol IOVA

Analyst Forecast

According to 9 analyst ratings, the average rating for IOVA stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 290.49% from the latest price.

Buy 88.89%
Hold 11.11%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Iovance Biotherapeutics Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $71.57M, reflecting a 14.75K% YoY growth and earnings per share of -0.27, making a -40.00% decrease YoY.
2 months ago · Source
-13.76%
Iovance Biotherapeutics shares are trading lower. ... Unlock content with Pro Subscription
2 months ago · Source
+1.15%
Iovance Biotherapeutics shares are trading lower. The company reported Q3 financial results.